首页> 外文期刊>Modern Pathology >Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified
【24h】

Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified

机译:整体exome测序揭示了FAT1肿瘤抑制基因的突变临床撞击外周T细胞淋巴瘤未另行指定

获取原文
       

摘要

Peripheral T-cell lymphoma not otherwise specified represents a diagnostic category comprising clinically, histologically, and molecularly heterogeneous neoplasms that are poorly understood. The genetic landscape of peripheral T-cell lymphoma not otherwise specified remains largely undefined, only a few sequencing studies having been conducted so far. In order to improve our understanding of the genetics of this neoplasm, we performed whole exome sequencing along with RNA-sequencing in a discovery set of 21 cases. According to whole exome sequencing results and mutations previously reported in other peripheral T-cell lymphomas, 137 genes were sequenced by a targeted deep approach in 71 tumor samples. In addition to epigenetic modifiers implicated in all subtypes of T-cell neoplasm (TET2, DNMT3A, KMT2D, KMT2C, SETD2), recurrent mutations of the FAT1 tumor suppressor gene were for the first time recorded in 39% of cases. Mutations of the tumor suppressor genes LATS1, STK3, ATM, TP53, and TP63 were also observed, although at a lower frequency. Patients with FAT1 mutations showed inferior overall survival compared to those with wild-type FAT1. Although peripheral T-cell lymphoma not otherwise specified remains a broad category also on molecular grounds, the present study highlights that FAT1 mutations occur in a significant proportion of cases, being provided with both pathogenetic and prognostic impact.
机译:未指定的外周T细胞淋巴瘤代表诊断类别,其包含临床,组织学和分子异质肿瘤,其知之甚少。外周T细胞淋巴瘤的遗传景观未指定仍未缺陷,目前仅进行了几项测序研究。为了改善我们对该肿瘤的遗传学的理解,我们在发现组21例的发现组中进行了全面的exome测序。根据以前在其他外周T细胞淋巴瘤中报道的全外壳测序结果和突变,通过71个肿瘤样品中的靶向深度方法测序137个基因。除了在T细胞肿瘤的所有亚型(TET2,DNMT3A,KMT2D,KMT2C,SETD2)中,FAT1肿瘤抑制基因的复发突变在39%的情况下记录的复发突变。还观察到肿瘤抑制基因LAT1,STK3,ATM,TP53和TP63的突变,但在较低的频率下。与野生型FAT1相比,患有FAT1突变的患者表现出较差的整体存活。虽然外周T细胞淋巴瘤未另行指定仍然是分子场上的广泛类别,但本研究突出显示FAT1突变在大量比例的情况下发生,随着致​​病性和预后的影响。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号